Psoriatic Arthritis Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2032

The Psoriatic Arthritis market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as UCB Biopharma, Sun Pharmaceutical Industries Limited, BMS, Affibody AB, Janssen Biotech, Amgen, Eli Lilly and Company, AbbVie, Pfizer, ACELYRIN Inc., Novartis, Pfizer, Amgen, UCB Biopharma SRL, Takeda, Bristol-Myers Squibb, Astellas Pharma Inc, Abbott.

[Nevada, United States] - DelveInsight's "Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast 2032." report offers a detailed examination of Psoriatic Arthritis, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Psoriatic Arthritis Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Psoriatic Arthritis Market Report:
The Psoriatic Arthritis market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).
In October, 2024: Novartis announced that the purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment
In October, 2024: Sun Pharmaceutical Industries Limited announced that Subjects from both INSPIRE 1 (TILD-19-07) and INSPIRE 2 (TILD-19-19) studies to roll over into this INSPIRE LTE study (TILD-21-01).
In October, 2024: AbbVie announced that their studies includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo and versus adalimumab (Humira®) in participants with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response to non-biologic DMARDs (DMARD-IR).
In October, 2024: Eli Lilly and Company announced that the purpose of their study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab.
In September, 2024: Bristol-Myers Squibb announced that the purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.
As per DelveInsight's assessment, in 2023, most of the PsA cases were of moderate severity, accounting for ~60% cases of pSA, followed by severe and mild type.
The highest cases of PsA were found in the age group 50-59 years, and the least number of cases were observed in 18-29 age group in the US in 2023.
As per DelveInsight's analysis, among the EU4 countries and the UK, Germany accounted for the highest number of cases of psoriatic arthritis (PsA) and Spain accounted for the lowest number of cases in 2023
Key Psoriatic Arthritis Companies are as follows: UCB Biopharma, Sun Pharmaceutical Industries Limited, BMS, Affibody AB, Janssen Biotech, Amgen, Eli Lilly and Company, AbbVie, Pfizer, ACELYRIN Inc., Novartis, Pfizer, Amgen, UCB Biopharma SRL, Takeda, Bristol-Myers Squibb, Astellas Pharma Inc, Abbott.
Key Psoriatic Arthritis Therapies are as follow: Izokibep, HS-10374, Secukinumab, Ustekinumab, Sonelokimab, Adalimumab, Bimekizumab, Tofacitinib, Apremilast, BAT2506, Guselkumab, Golimumab, AIN457 3 mg/kg, ACTHar, Deucravacitinib, Apremilast, NDI-034858, methotrexate, Etanercept, Methotrexate
Launching multiple stage Psoriatic Arthritis pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Psoriatic Arthritis market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Psoriatic Arthritis Overview:
Psoriatic arthritis (PsA) is a form of arthritis associated with psoriasis, chronic skin and nail disease characterized by red, scaly rashes and thick pitted fingernails. Psoriatic arthritis (PsA) resembles rheumatoid arthritis (RA) in symptoms characterized by joint inflammation. However, psoriatic arthritis (PsA) affects fewer joints than RA and does not produce the typical RA antibodies.

Psoriatic Arthritis Epidemiology Segmentation:
The Psoriatic Arthritis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
Psoriatic Arthritis Total Prevalent Cases
Psoriatic Arthritis Total Diagnosed Cases
Psoriatic Arthritis Gender-specific Cases
Psoriatic Arthritis Age-specific Cases

For more information about Psoriatic Arthritis companies working in the treatment market, visit https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Psoriatic Arthritis Market Insights
Treatment approaches for psoriatic arthritis (PsA) encompass a variety of strategies aimed at managing symptoms, slowing disease progression, and improving overall quality of life. These approaches typically involve a combination of pharmacological therapies, lifestyle modifications, and, in some cases, surgical interventions. Overall, the treatment approach for PsA is individualized based on disease severity, response to therapy, and patient preferences.

Multidisciplinary care involving rheumatologists, dermatologists, physical therapists, and other healthcare professionals is essential to optimize outcomes and improve the long-term prognosis for individuals living with PsA

Psoriatic Arthritis Drugs Uptake
TNF Inhibitors: Drugs like adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade) continue to be widely prescribed due to their long-established efficacy. These biologics target the TNF-alpha protein involved in inflammation.
IL-17 Inhibitors: IL-17 inhibitors, such as secukinumab (Cosentyx) and ixekizumab (Taltz), have gained significant market share due to their efficacy in treating both skin and joint symptoms. These drugs are especially beneficial for patients who do not respond to TNF inhibitors.
JAK Inhibitors: Tofacitinib (Xeljanz), a JAK inhibitor, is increasingly used for patients with moderate-to-severe PsA, offering an oral option with potent anti-inflammatory effects.
Traditional DMARDs such as methotrexate and sulfasalazine remain first-line treatments, especially for patients with less severe disease. However, the uptake of biologics and small molecules has reduced reliance on DMARDs, particularly in moderate-to-severe cases.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Psoriatic Arthritis Therapies and Key Companies:
Izokibep: ACELYRIN Inc.
HS-10374: Hansoh BioMedical R&D Company
Secukinumab, Ustekinumab: Novartis Pharmaceuticals
Sonelokimab, Adalimumab: MoonLake Immunotherapeutics AG
Bimekizumab: UCB Biopharma SRL
Tofacitinib: Pfizer
Apremilast: Amgen
BAT2506: Bio-Thera Solutions
Guselkumab, Golimumab: Janssen Research & Development, LLC
AIN457 3 mg/kg: Novartis Pharmaceuticals
ACTHar: IRIS Research and Development, LLC
Deucravacitinib, Apremilast: Bristol-Myers Squibb
NDI-034858: Takeda
methotrexate: AbbVie
Etanercept, Methotrexate: Amgen

Psoriatic Arthritis Epidemiology:
Psoriatic arthritis affects a subset of individuals with psoriasis, a common autoimmune skin condition. PsA can develop at any age, though it typically occurs between the ages of 30 and 50. The global prevalence of PsA ranges from 0.1% to 1%, but it is estimated that between 20% to 30% of patients with psoriasis develop PsA. The incidence of PsA has been rising due to better awareness and diagnosis.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Psoriatic Arthritis Market Drivers:
Growing Prevalence and Diagnosis Rates
Advancements in Targeted Therapies
Patient and Physician Demand for Better Therapies
Pipeline Innovation and Drug Approvals

Psoriatic Arthritis Market Barriers:
Safety Concerns and Side Effects
Access and Reimbursement Issues
Treatment Durability and Response Variability
Competition from Biosimilars

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Psoriatic Arthritis Market Report:
Study Period: 2019-2032
Coverage: 7MM (The United States, EU5, and Japan)
Key Psoriatic Arthritis Companies: UCB Biopharma, Sun Pharmaceutical Industries Limited, BMS, Affibody AB, Janssen Biotech, Amgen, Eli Lilly and Company, AbbVie, Pfizer, ACELYRIN Inc., Novartis, Pfizer, Amgen, UCB Biopharma SRL, Takeda, Bristol-Myers Squibb, Astellas Pharma Inc, Abbott.
Key Psoriatic Arthritis Therapies: Izokibep, HS-10374, Secukinumab, Ustekinumab, Sonelokimab, Adalimumab, Bimekizumab, Tofacitinib, Apremilast, BAT2506, Guselkumab, Golimumab, AIN457 3 mg/kg, ACTHar, Deucravacitinib, Apremilast, NDI-034858, methotrexate, Etanercept, Methotrexate
Psoriatic Arthritis Therapeutic Assessment: Current marketed and emerging therapies
Psoriatic Arthritis Market Dynamics: Psoriatic Arthritis Market drivers and Psoriatic Arthritis barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Psoriatic Arthritis Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Psoriatic Arthritis market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Psoriatic Arthritis Market Overview at a Glance
4. Executive Summary of Psoriatic Arthritis
5. Disease Background and Overview
6. Epidemiology and Patient Population
7. Patient Journey of Psoriatic Arthritis
8. Marketed Products
9. Emerging Therapies
10. Other Assets
11. Psoriatic Arthritis (PsA): Seven Major Market Analysis
12. SWOT Analysis
13. KOL Views
14. Unmet Needs
15. Market Access
16. Acronyms and Abbreviations
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.